Matrix stiffening related lncRNA SNHG8 regulates chemosensitivity of ovarian cancer_Journal of Biomedical Engineering

Authors：

CHENG Zina ¹ ,  MA Xiaolu ^1,2 , ZHANG Quanyou ¹ , CHEN Weiyi ¹

1. College of Biomedical Engineering, Taiyuan University of Technology, Taiyuan 030024, P. R. China;
2. Institute of Zoology, University of Chinese Academy of Sciences, Beijing 100101, P. R. China;

Corresponding author：

MA Xiaolu, Email: maxiaolu@tyut.edu.cn

Keywords：

Matrix stiffness; Long non-coding RNA; SNHG8; Ovarian cancer; Chemosensitivity

DOI：

10.7507/1001-5515.202205038

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Extracellular matrix (ECM) has been implicated in tumor progress and chemosensitivity. Ovarian cancer brings a great threat to the health of women with a significant feature of high mortality and poor prognosis. However, the potential significance of matrix stiffness in the pattern of long non-coding RNAs (lncRNAs) expression and ovarian cancer drug sensitivity is still largely unkown. Here, based on RNA-seq data of ovarian cancer cell cultured on substrates with different stiffness, we found that a great amount of lncRNAs were upregulated in stiff group, whereas SNHG8 was significantly downregulated, which was further verified in ovarian cancer cells cultured on polydimethylsiloxane (PDMS) hydrogel. Knockdown of SNHG8 led to an impaired efficiency of homologous repair, and decreased cellular sensitivity to both etoposide and cisplatin. Meanwhile, the results of the GEPIA analysis indicated that the expression of SNHG8 was significantly decreased in ovarian cancer tissues, which was negatively correlated with the overall survival of patients with ovarian cancer. In conclusion, matrix stiffening related lncRNA SNHG8 is closely related to chemosensitivity and prognosis of ovarian cancer, which might be a novel molecular marker for chemotherapy drug instruction and prognosis prediction.

Citation： CHENG Zina, MA Xiaolu, ZHANG Quanyou, CHEN Weiyi. Matrix stiffening related lncRNA SNHG8 regulates chemosensitivity of ovarian cancer. Journal of Biomedical Engineering, 2023, 40(1): 87-94. doi: 10.7507/1001-5515.202205038 Copy

1.	Siegel R L, Miller K D, Jemal A. Cancer statistics, 2017. CA Cancer J. Clin, 2015, 60(1): 277-300.
2.	Zhang Q, Ding J, Wang Y, et al. Tumor microenvironment manipulates chemoresistance in ovarian cancer. Oncol Rep, 2022, 47(5): 1-7.
3.	Gogineni V, Morand S, Staats H, et al. Current ovarian cancer maintenance strategies and promising new developments. J CANCER, 2021, 12(1): 38-53.
4.	马丁. 卵巢癌研究进展与规范化治疗. 中国实用妇科与产科杂志, 2021, 37(6): 601-604.
5.	Kinoshita T, Goto T. Molecular mechanisms of pulmonary fibrogenesis and its progression to lung cancer: A review. Int J Mol Sci, 2019, 20(6): 1461.
6.	Schrader J, Gordon-Walker T T, Aucott R L, et al. Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells. Hepatology, 2011, 53(4): 1192-1205.
7.	于淑婷, 张怡, 朱佳润,等. CECMAtlas 1. 0:人类肿瘤相关的细胞外基质基因数据库. 中国生物化学与分子生物学报, 2021, 37(2): 207-213.
8.	Mccabe EM, Rasmussen TP. LncRNA involvement in cancer stem cell function and epithelial-mesenchymal transitions. Semin Cancer, 2021, 75: 38-48.
9.	原佳沛, 张浩文, 鲁志. 新型长链非编码RNA(lncRNA)的生物信息学研究进展. 生物化学与生物物理进展, 2013, 40(7): 634-640.
10.	Bing X, Sheng Q, Nakanishi K, et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell, 2006, 22(6): 719-729.
11.	Landry D A, Vaishnav H T, Vanderhyden BC. The significance of ovarian fibrosis. Oncotarget, 2020, 11(47): 4366-4370.
12.	Ames J J, Caron J M, Contois L, et al. Abstract 1480: Regulation of ovarian tumor growth and stromal cell infiltration by the HU177 biomechanical ECM switch. Cancer Res, 2012, 72(8 Supplement): 1480-1480.
13.	Rice A J, Cortes E, Lachowski D, et al. Matrix stiffness induces epithelial–mesenchymal transition and promotes chemoresistance in pancreatic cancer cells. Oncogenesis, 2017, 6(7): e352.
14.	Dupont S, Morsut L, Aragona M, et al. Role of YAP/TAZ in mechanotransduction. Nature, 2011, 474(7350): 179-183.
15.	Aragona M, Panciera T, Manfrin A, et al. A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. Cell, 2013, 154(5): 1047-1059.
16.	Fan Y, Sun Q, Li X, et al. Substrate stiffness modulates the growth, phenotype, and chemoresistance of ovarian cancer cells. Front Cell Dev Biol, 2021: 2263.
17.	Wu X , Cao X B , F Chen. LncRNA-HOTAIR activates tumor cell proliferation and migration by suppressing MiR-326 in cervical cancer. Oncol Res, 2017.
18.	Bian Z, Zhang J, Min L, et al. 1 LncRNA—FEZF1-AS1 promotes tumor proliferation and metastasis in 2 colorectal cancer by regulating PKM2 signaling. Clin Cancer Res, 2018: clincanres.2967.2017-.
19.	Ou L, Wang D, Zhang H, et al. Decreased expression of MiR-138-5p by lncRNA H19 in cervical cancer promotes tumor proliferation. Oncol Res, 2017, 26(3): 401.
20.	Dong Y, Liang G, Yuan B, et al. MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the PI3K/Akt pathway. Tumor Biol, 2015, 36(3): 1477.
21.	Liu J, Peng W X, Mo Y Y, et al. MALAT1-mediated tumorigenesis. Front Biosci, 2017, 22: 66-80.
22.	Oien D B, Chien J, Cheng N. Regulation of chemo-sensitivity in ovarian cancer via a stroma dependent glutathione pathway. Transl Cancer Res, 2016, 5(S3): S514-S519.
23.	Xuan L, Sun Z, Wang J, et al. lncRNA SNHG8 promotes ovarian cancer progression through serving as sponge for miR70 to regulate S100A11 expression. J Gene Med, 2021.
24.	Huang T, Ji Y, Hu D, et al. SNHG8 is identified as a key regulator of epstein-barr virus(EBV)-associated gastric cancer by an integrative analysis of lncRNA and mRNA expression. Oncotarget, 2016, 7(49).
25.	Chen C, Zhang Z, Li J, et al. SNHG8 is identified as a key regulator in non-small-cell lung cancer progression sponging to miR-542-3p by targeting CCND1/CDK6 [Erratum].Oncotargets Ther, 2018, Volume 11: 8013-8014.
26.	Lin Y, Hu D, Zhou Q, et al. The fasting blood glucose and long non-coding RNA SNHG8 predict poor prognosis in patients with gastric carcinoma after radical gastrectomy. Aging, 2018, 10(10): 2646-2656.
27.	Song Y, Zou L, Li J, et al. LncRNA SNHG8 promotes the development and chemo-resistance of pancreatic adenocarcinoma. Eur Rev Med Pharmaco, 2018, 22(23): 8161-8168.
28.	Xu Xianyun, Xie Qiongjun, Xie Mingfeng, et al. LncRNA SNHG8 serves as an oncogene in breast cancer through miR-634/ZBTB20 Axis. Cancer Manag Res, 2021, 13: 3017-3028.
29.	Clevers H, Nusse R. Wnt/β-Catenin signaling and disease. Cell, 2012, 149(6): 1192-1205.
30.	Miao W, Lu T, Liu X, et al. LncRNA SNHG8 induces ovarian carcinoma cells cellular process and stemness through Wnt/β-catenin pathway. Cancer Biomark, 2020, 28(4): 1-13.

1. Siegel R L, Miller K D, Jemal A. Cancer statistics, 2017. CA Cancer J. Clin, 2015, 60(1): 277-300.
2. Zhang Q, Ding J, Wang Y, et al. Tumor microenvironment manipulates chemoresistance in ovarian cancer. Oncol Rep, 2022, 47(5): 1-7.
3. Gogineni V, Morand S, Staats H, et al. Current ovarian cancer maintenance strategies and promising new developments. J CANCER, 2021, 12(1): 38-53.
4. 马丁. 卵巢癌研究进展与规范化治疗. 中国实用妇科与产科杂志, 2021, 37(6): 601-604.
5. Kinoshita T, Goto T. Molecular mechanisms of pulmonary fibrogenesis and its progression to lung cancer: A review. Int J Mol Sci, 2019, 20(6): 1461.
6. Schrader J, Gordon-Walker T T, Aucott R L, et al. Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells. Hepatology, 2011, 53(4): 1192-1205.
7. 于淑婷, 张怡, 朱佳润,等. CECMAtlas 1. 0:人类肿瘤相关的细胞外基质基因数据库. 中国生物化学与分子生物学报, 2021, 37(2): 207-213.
8. Mccabe EM, Rasmussen TP. LncRNA involvement in cancer stem cell function and epithelial-mesenchymal transitions. Semin Cancer, 2021, 75: 38-48.
9. 原佳沛, 张浩文, 鲁志. 新型长链非编码RNA(lncRNA)的生物信息学研究进展. 生物化学与生物物理进展, 2013, 40(7): 634-640.
10. Bing X, Sheng Q, Nakanishi K, et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell, 2006, 22(6): 719-729.
11. Landry D A, Vaishnav H T, Vanderhyden BC. The significance of ovarian fibrosis. Oncotarget, 2020, 11(47): 4366-4370.
12. Ames J J, Caron J M, Contois L, et al. Abstract 1480: Regulation of ovarian tumor growth and stromal cell infiltration by the HU177 biomechanical ECM switch. Cancer Res, 2012, 72(8 Supplement): 1480-1480.
13. Rice A J, Cortes E, Lachowski D, et al. Matrix stiffness induces epithelial–mesenchymal transition and promotes chemoresistance in pancreatic cancer cells. Oncogenesis, 2017, 6(7): e352.
14. Dupont S, Morsut L, Aragona M, et al. Role of YAP/TAZ in mechanotransduction. Nature, 2011, 474(7350): 179-183.
15. Aragona M, Panciera T, Manfrin A, et al. A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. Cell, 2013, 154(5): 1047-1059.
16. Fan Y, Sun Q, Li X, et al. Substrate stiffness modulates the growth, phenotype, and chemoresistance of ovarian cancer cells. Front Cell Dev Biol, 2021: 2263.
17. Wu X , Cao X B , F Chen. LncRNA-HOTAIR activates tumor cell proliferation and migration by suppressing MiR-326 in cervical cancer. Oncol Res, 2017.
18. Bian Z, Zhang J, Min L, et al. 1 LncRNA—FEZF1-AS1 promotes tumor proliferation and metastasis in 2 colorectal cancer by regulating PKM2 signaling. Clin Cancer Res, 2018: clincanres.2967.2017-.
19. Ou L, Wang D, Zhang H, et al. Decreased expression of MiR-138-5p by lncRNA H19 in cervical cancer promotes tumor proliferation. Oncol Res, 2017, 26(3): 401.
20. Dong Y, Liang G, Yuan B, et al. MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the PI3K/Akt pathway. Tumor Biol, 2015, 36(3): 1477.
21. Liu J, Peng W X, Mo Y Y, et al. MALAT1-mediated tumorigenesis. Front Biosci, 2017, 22: 66-80.
22. Oien D B, Chien J, Cheng N. Regulation of chemo-sensitivity in ovarian cancer via a stroma dependent glutathione pathway. Transl Cancer Res, 2016, 5(S3): S514-S519.
23. Xuan L, Sun Z, Wang J, et al. lncRNA SNHG8 promotes ovarian cancer progression through serving as sponge for miR70 to regulate S100A11 expression. J Gene Med, 2021.
24. Huang T, Ji Y, Hu D, et al. SNHG8 is identified as a key regulator of epstein-barr virus(EBV)-associated gastric cancer by an integrative analysis of lncRNA and mRNA expression. Oncotarget, 2016, 7(49).
25. Chen C, Zhang Z, Li J, et al. SNHG8 is identified as a key regulator in non-small-cell lung cancer progression sponging to miR-542-3p by targeting CCND1/CDK6 [Erratum].Oncotargets Ther, 2018, Volume 11: 8013-8014.
26. Lin Y, Hu D, Zhou Q, et al. The fasting blood glucose and long non-coding RNA SNHG8 predict poor prognosis in patients with gastric carcinoma after radical gastrectomy. Aging, 2018, 10(10): 2646-2656.
27. Song Y, Zou L, Li J, et al. LncRNA SNHG8 promotes the development and chemo-resistance of pancreatic adenocarcinoma. Eur Rev Med Pharmaco, 2018, 22(23): 8161-8168.
28. Xu Xianyun, Xie Qiongjun, Xie Mingfeng, et al. LncRNA SNHG8 serves as an oncogene in breast cancer through miR-634/ZBTB20 Axis. Cancer Manag Res, 2021, 13: 3017-3028.
29. Clevers H, Nusse R. Wnt/β-Catenin signaling and disease. Cell, 2012, 149(6): 1192-1205.
30. Miao W, Lu T, Liu X, et al. LncRNA SNHG8 induces ovarian carcinoma cells cellular process and stemness through Wnt/β-catenin pathway. Cancer Biomark, 2020, 28(4): 1-13.

Journal of Biomedical Engineering

Matrix stiffening related lncRNA SNHG8 regulates chemosensitivity of ovarian cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content